Snow Storm Offers Sarepta Reprieve From FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
No make-up date announced after weather worries force postponement, but Sarepta now has more time to contemplate answers to FDA questions about its Duchenne muscular dystrophy candidate eteplirsen.